vs
ANI PHARMACEUTICALS INC（ANIP）とAPOGEE ENTERPRISES, INC.（APOG）の財務データ比較。上の社名をクリックして会社を切り替えられます
APOGEE ENTERPRISES, INC.の直近四半期売上が大きい（$351.4M vs $247.1M、ANI PHARMACEUTICALS INCの約1.4倍）。ANI PHARMACEUTICALS INCの純利益率が高く（11.1% vs 4.7%、差は6.4%）。ANI PHARMACEUTICALS INCの前年同期比売上増加率が高い（29.6% vs 1.6%）。過去8四半期でANI PHARMACEUTICALS INCの売上複合成長率が高い（34.1% vs 2.9%）
ANIファーマシューティカルズは米国に本社を置く特殊製薬会社で、後発医薬品とブランド処方薬の研究開発・製造・販売を行っています。主力製品分野は皮膚科、腫瘍、中枢神経系治療、感染症対策で、主に米国内の医療機関、調剤薬局、患者を対象としています。
Apogee Enterprisesはアメリカのオーディオ機器メーカーです。オーディオインターフェース、AD/DAコンバーター、USB・iOS対応マイクの製造を主軸に、オーディオ制作向けソフトウェアの開発も手がけており、プロの録音や音楽制作分野で広く利用されています。
ANIP vs APOG — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $247.1M | $351.4M |
| 純利益 | $27.5M | $16.6M |
| 粗利率 | — | 22.4% |
| 営業利益率 | 14.1% | 7.3% |
| 純利益率 | 11.1% | 4.7% |
| 売上前年比 | 29.6% | 1.6% |
| 純利益前年比 | 367.5% | 568.8% |
| EPS（希薄化後） | $1.14 | $0.78 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q1 26 | — | $351.4M | ||
| Q4 25 | $247.1M | $348.6M | ||
| Q3 25 | $227.8M | $358.2M | ||
| Q2 25 | $211.4M | $346.6M | ||
| Q1 25 | $197.1M | $345.7M | ||
| Q4 24 | $190.6M | $341.3M | ||
| Q3 24 | $148.3M | $342.4M | ||
| Q2 24 | $138.0M | $331.5M |
| Q1 26 | — | $16.6M | ||
| Q4 25 | $27.5M | $16.5M | ||
| Q3 25 | $26.6M | $23.6M | ||
| Q2 25 | $8.5M | $-2.7M | ||
| Q1 25 | $15.7M | $2.5M | ||
| Q4 24 | $-10.3M | $21.0M | ||
| Q3 24 | $-24.2M | $30.6M | ||
| Q2 24 | $-2.3M | $31.0M |
| Q1 26 | — | 22.4% | ||
| Q4 25 | — | 23.8% | ||
| Q3 25 | — | 23.1% | ||
| Q2 25 | — | 21.7% | ||
| Q1 25 | — | 21.6% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | — | 28.4% | ||
| Q2 24 | — | 29.8% |
| Q1 26 | — | 7.3% | ||
| Q4 25 | 14.1% | 7.1% | ||
| Q3 25 | 15.9% | 7.5% | ||
| Q2 25 | 6.6% | 2.0% | ||
| Q1 25 | 13.3% | 1.8% | ||
| Q4 24 | -2.3% | 8.4% | ||
| Q3 24 | -13.8% | 12.3% | ||
| Q2 24 | 3.7% | 12.5% |
| Q1 26 | — | 4.7% | ||
| Q4 25 | 11.1% | 4.7% | ||
| Q3 25 | 11.7% | 6.6% | ||
| Q2 25 | 4.0% | -0.8% | ||
| Q1 25 | 8.0% | 0.7% | ||
| Q4 24 | -5.4% | 6.1% | ||
| Q3 24 | -16.3% | 8.9% | ||
| Q2 24 | -1.7% | 9.4% |
| Q1 26 | — | $0.78 | ||
| Q4 25 | $1.14 | $0.77 | ||
| Q3 25 | $1.13 | $1.10 | ||
| Q2 25 | $0.36 | $-0.13 | ||
| Q1 25 | $0.69 | $0.12 | ||
| Q4 24 | $-0.45 | $0.96 | ||
| Q3 24 | $-1.27 | $1.40 | ||
| Q2 24 | $-0.14 | $1.41 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $285.6M | $39.5M |
| 総負債低いほど良い | — | $232.3M |
| 株主資本純資産 | $540.7M | $511.8M |
| 総資産 | $1.4B | $1.1B |
| 負債/資本比率低いほどレバレッジが低い | — | 0.45× |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | $39.5M | ||
| Q4 25 | $285.6M | $41.3M | ||
| Q3 25 | $262.6M | $39.5M | ||
| Q2 25 | $217.8M | $32.8M | ||
| Q1 25 | $149.8M | $41.4M | ||
| Q4 24 | $144.9M | $43.9M | ||
| Q3 24 | $145.0M | $51.0M | ||
| Q2 24 | $240.1M | $30.4M |
| Q1 26 | — | $232.3M | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $285.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $511.8M | ||
| Q4 25 | $540.7M | $512.3M | ||
| Q3 25 | $505.8M | $500.2M | ||
| Q2 25 | $436.8M | $481.8M | ||
| Q1 25 | $418.6M | $487.9M | ||
| Q4 24 | $403.7M | $522.1M | ||
| Q3 24 | $405.9M | $506.4M | ||
| Q2 24 | $455.8M | $480.0M |
| Q1 26 | — | $1.1B | ||
| Q4 25 | $1.4B | $1.1B | ||
| Q3 25 | $1.4B | $1.2B | ||
| Q2 25 | $1.3B | $1.2B | ||
| Q1 25 | $1.3B | $1.2B | ||
| Q4 24 | $1.3B | $1.2B | ||
| Q3 24 | $1.3B | $917.1M | ||
| Q2 24 | $920.8M | $889.0M |
| Q1 26 | — | 0.45× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $30.4M | $122.5M |
| フリーキャッシュフロー営業CF - 設備投資 | $29.1M | — |
| FCFマージンFCF / 売上 | 11.8% | — |
| 設備投資強度設備投資 / 売上 | 0.5% | 7.8% |
| キャッシュ転換率営業CF / 純利益 | 1.10× | 7.37× |
| 直近12ヶ月FCF直近4四半期 | $171.4M | — |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | $122.5M | ||
| Q4 25 | $30.4M | $29.3M | ||
| Q3 25 | $44.1M | $57.1M | ||
| Q2 25 | $75.8M | $-19.8M | ||
| Q1 25 | $35.0M | $30.0M | ||
| Q4 24 | $15.9M | $31.0M | ||
| Q3 24 | $12.5M | $58.7M | ||
| Q2 24 | $17.4M | $5.5M |
| Q1 26 | — | — | ||
| Q4 25 | $29.1M | $22.9M | ||
| Q3 25 | $38.0M | $52.4M | ||
| Q2 25 | $71.8M | $-26.9M | ||
| Q1 25 | $32.5M | $19.1M | ||
| Q4 24 | $13.5M | $22.0M | ||
| Q3 24 | $7.7M | $50.2M | ||
| Q2 24 | $13.0M | $-1.8M |
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | 6.6% | ||
| Q3 25 | 16.7% | 14.6% | ||
| Q2 25 | 34.0% | -7.8% | ||
| Q1 25 | 16.5% | 5.5% | ||
| Q4 24 | 7.1% | 6.4% | ||
| Q3 24 | 5.2% | 14.7% | ||
| Q2 24 | 9.4% | -0.5% |
| Q1 26 | — | 7.8% | ||
| Q4 25 | 0.5% | 1.9% | ||
| Q3 25 | 2.7% | 1.3% | ||
| Q2 25 | 1.9% | 2.1% | ||
| Q1 25 | 1.3% | 3.2% | ||
| Q4 24 | 1.3% | 2.6% | ||
| Q3 24 | 3.2% | 2.5% | ||
| Q2 24 | 3.2% | 2.2% |
| Q1 26 | — | 7.37× | ||
| Q4 25 | 1.10× | 1.77× | ||
| Q3 25 | 1.66× | 2.41× | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | 12.08× | ||
| Q4 24 | — | 1.48× | ||
| Q3 24 | — | 1.92× | ||
| Q2 24 | — | 0.18× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
APOG
| Architectural Services | $127.1M | 36% |
| Architectural Metals | $110.0M | 31% |
| Architectural Glass | $67.4M | 19% |
| Performance Surfaces | $54.3M | 15% |
